Claims
- 1. A compound of formula (I) ##STR22## wherein: R.sup.1 is other than in the ortho position and is: ##STR23## R.sup.2 is (a) H,
- (b) halo (F, Cl, Br, I),
- (c) C.sub.1 -C.sub.4 alkyl,
- (d) C.sub.1 -C.sub.4 alkoxy,
- (e) C.sub.1 -C.sub.4 acyloxy,
- (f) C.sub.1 -C.sub.4 alkylthio,
- (g) C.sub.1 -C.sub.4 alkylsulfinyl,
- (h) C.sub.1 -C.sub.4 alkylsulfonyl,
- (i) hydroxy (C.sub.1 -C.sub.4) alkyl,
- (j) phenyl (C.sub.1 -C.sub.4) alkyl,
- (k) --CO.sub.2 H,
- (l) --CN,
- (m) --CONHOR.sup.12,
- (n) --SO.sub.2 NHR.sup.21,
- (o) --NH.sub.2,
- (p) C.sub.1 -C.sub.4 alkylamino,
- (q) C.sub.1 -C.sub.4 dialkylamino,
- (r) --NHSO.sub.2 R.sup.20,
- (s) --NO.sub.2,
- (t) furyl,
- (u) aryl; wherein aryl is phenyl optionally substituted with one or two substituents selected from the group consisting of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --NO.sub.2, CF.sub.3, C.sub.1 -C.sub.4 alkylthio, --OH, --NH.sub.2, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, --CN, --CO.sub.2 H, --CO.sub.2 CH.sub.3, --CO.sub.2 CH.sub.2 CH.sub.3, --CO.sub.2 -benzyl;
- R.sup.3 is
- (a) H,
- (b) halo,
- (c) C.sub.1 -C.sub.4 alkyl,
- (d) C.sub.1 -C.sub.4 alkoxy,
- (e) C.sub.1 -C.sub.4 alkoxyalkyl;
- R.sup.4 is
- (a) --CN,
- (b) --NO.sub.2,
- (c) --CO.sub.2 R.sup.11,
- R.sup.5 is
- (a) H,
- (b) C.sub.1 -C.sub.6 alkyl,
- (c) C.sub.3 -C.sub.6 cycloalkyl,
- (d) C.sub.2 -C.sub.4 alkenyl,
- (e) C.sub.2 -C.sub.4 alkynyl;
- R.sup.6 is
- (a) C.sub.1 -C.sub.10 alkyl,
- (b) C.sub.3 -C.sub.8 alkenyl,
- (c) C.sub.3 -C.sub.8 alkynyl,
- (d) C.sub.3 -C.sub.8 cycloalkyl,
- (e) C.sub.4 -C.sub.8 cycloalkenyl,
- (f) C.sub.4 -C.sub.10 cycloalkylalkyl,
- (g) C.sub.5 -C.sub.10 cycloalkylalkenyl,
- (h) C.sub.5 -C.sub.10 cycloalkylalkynyl,
- (i) --(CH.sub.2)SZ(CH.sub.2).sub.m R.sup.5,
- (j) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --NO.sub.2, --NH.sub.2, --OH and benzyloxy,
- (k) benzyl, optionally substituted on the phenyl ring with 1-2 substituents selected from the group of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and --NO.sub.2 ;
- R.sup.7 and R.sup.8 taken together are --(CH.sub.2).sub.t --,
- R.sup.9 and R.sup.10 taken together are O;
- R.sup.11 is
- (a) H,
- (b) C.sub.1 -C.sub.4 alkyl,
- (c) C.sub.1 -C.sub.4 cycloalkyl,
- (d) phenyl,
- (e) benzyl;
- R.sup.12 is
- (a) H,
- (b) methyl,
- (c) benzyl;
- R.sup.13 is
- (a) --CH.sub.2 CO.sub.2 H,
- (b) --C(CF.sub.3).sub.2 OH,
- (c) --CONHNHSO.sub.2 CF.sub.3,
- (d) --CONHOR.sup.12,
- (e) --CONHSO.sub.2 R.sup.20,
- (f) --CONHSO.sub.2 NHR.sup.19,
- (g) --C(OH)R.sup.19 PO.sub.3 H.sub.2,
- (h) --NHCONHSO.sub.2 R.sup.20,
- (i) --NHPO.sub.3 H.sub.2,
- (j) --SO.sub.2 NHCOR.sup.20,
- (k) --OPO.sub.3 H.sub.2,
- (l) --OSO.sub.3 H,
- (m) --PO(OH)R.sup.19,
- (n) --PO.sub.3 H.sub.2,
- (o) --SO.sub.3 H,
- (p) --SO.sub.2 NHR.sup.19,
- (q) --NHSO.sub.2 NHCOR.sup.20,
- (r) --SO.sub.2 NHCONHR.sup.19, ##STR24## R.sup.19 is (a) H,
- (b) C.sub.1 -C.sub.5 alkyl optionally substituted with a substituent selected from the group consisting of aryl, as defined above, --OH, --SH, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, --CF.sub.3, halo, --NO.sub.2, --CO.sub.2 H, --CO.sub.2 CH.sub.3, --CO.sub.2 -benzyl, --NH.sub.2, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, --PO.sub.3 H.sub.2,
- (c) aryl, as defined above,
- (d) benzyl
- R.sup.20 is
- (a) aryl, as defined above,
- (b) C.sub.3 -C.sub.7 cycloalkyl,
- (c) C.sub.1 -C.sub.4 perfluoroalkyl,
- (d) C.sub.1 -C.sub.4 alkyl optionally substituted with a substituent selected from the group consisting of aryl, as defined above, --OH, --SH, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, --CF.sub.3, halo, --NO.sub.2, --CO.sub.2 H, --CO.sub.2 CH.sub.3, --CO.sub.2 -benzyl, --NH.sub.2, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, --PO.sub.3 H.sub.2,
- (e) C.sub.1 -C.sub.4 alkoxy optionally substituted with a substituent selected from the group consisting of aryl as defined above, --OH, --SH, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, --CF.sub.3, halo, --NO.sub.2, --CO.sub.2 H, --CO.sub.2 CH.sub.3, --CO.sub.2 -benzyl, --NH.sub.2, C.sub.1 -C.sub.4 alkylamino, C.sub.1 -C.sub.4 dialkylamino, --PO.sub.3 H.sub.2,
- (f) furyl;
- (g) thienyl;
- R.sup.21 is
- (a) H,
- (b) C.sub.1 -C.sub.6 alkyl,
- (c) phenyl,
- (d) benzyl;
- Z is
- (a) --O--,
- (b) --S--,
- (c) --NR.sup.11 --;
- m is 1 to 5;
- n is 1 to 4;
- t is 2 to 5;
- or a pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1 wherein R.sup.1 is in the para position and is ##STR25## R.sup.6 is (a) C.sub.1 -C.sub.10 alkyl,
- (b) C.sub.3 -C.sub.10 alkenyl,
- (c) C.sub.3 -C.sub.10 alkynyl,
- (d) C.sub.3 -C.sub.8 cycloalkyl,
- (e) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --NO.sub.2, --NH.sub.2, --OH and benzyloxy,
- (f) benzyl, optionally substituted on the phenyl ring with one or two substituents selected from the group consisting of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and --NO.sub.2 ;
- R.sup.7 and R.sup.8 taken together are --(CH.sub.2).sub.4 --,
- R.sup.9 and R.sup.10 taken together are O;
- R.sup.13 is
- (a) --CONHSO.sub.2 R.sup.20 ;
- (b) --NHCONHSO.sub.2 R.sup.20,
- (c) --NHSO.sub.2 NHCOR.sup.20,
- (d) --PO.sub.3 H.sub.2,
- (e) --SO.sub.3 H,
- (f) --SO.sub.2 NHR.sup.19,
- (g) --SO.sub.2 NHCOR.sup.20,
- (h) --SO.sub.2 NHCONHR.sup.19,
- (i) ##STR26## or a pharmaceutically acceptable salt thereof.
- 3. A compound of claim 2 wherein
- R.sup.6 is
- (a) C.sub.1 -C.sub.7 alkyl,
- (b) C.sub.3 -C.sub.4 alkenyl,
- (c) C.sub.3 -C.sub.4 alkynyl,
- (d) phenyl, optionally substituted with 1-2 substituents selected from the group of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --NO.sub.2, --NH.sub.2, --OH and benzyloxy;
- R.sup.13 is
- (a) --CONHSO.sub.2 R.sup.20,
- (b) --NHCONHSO.sub.2 R.sup.20,
- (c) --SO.sub.2 NHR.sup.19,
- (d) --SO.sub.2 NHCONHR.sup.19,
- (e) --SO.sub.2 NHCOR.sup.20,
- (f) --SO.sub.2 NHCONHR.sup.19 ;
- or a pharmaceutically acceptable salt thereof.
- 4. A compound of claim 3 wherein R.sup.1 is ##STR27## or a pharmaceutically acceptable salt thereof.
- 5. A compound of claim 4 selected from the group consisting of
- N- 4'- 4-oxo-2-butyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl!(1,1'-biphenyl-2-ylsulfonyl)!-benzamide
- N- 4'- 4-oxo-2-butyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl!(1,1'-biphenyl-2-ylsulfonyl)!-benzamide
- N- 4'- 4-oxo-2-propyl-1,3-diazaspiro 2.4!hept-1-en-3-yl!methyl! (1,1'-biphenyl-2-ylsulfonyl)!-hexanamide
- N- 4'- 4-oxo-2-propyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl!(1,1'-biphenyl-2-ylsulfonyl)!-hexanamide
- N- 4'- 4-oxo-2-propyl-1,3-diazaspiro 4.5!dec-1-en-3-yl!methyl!(1,1'-biphenyl-2-ylsulfonyl)!-hexanamide
- N- 4'- 4-oxo-2-butyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl!(1,1'-biphenyl-2-ylsulfonyl)!-hexanamide
- N- 4'- 4-oxo-2-propyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl! (3-chloro-(1,1'-biphenyl-2-ylsulfonyl)!!-carbamic acid, n-butyl ester
- N- 4'- 4-oxo-2-propyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl!(1,1'-biphenyl-2-ylsulfonyl)!-carbamic acid, 2-methylpropyl ester
- N- 4'- 4-oxo-2-propyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl! 3'-methyl (1,1'-biphenyl-2-ylsulfonyl)!!-carbamic acid, n-butyl ester
- N- 4'- 4-oxo-2-propyl-1,3-diazaspiro 4.4!non-1-en-3-yl!methyl! 4-propyl(1,1'-biphenyl-2-ylsulfonyl)!!carbamic acid, n-butyl ester.
- 6. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a compound of any one of claims 1 through 4.
- 7. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a compound of claim 5.
- 8. A method of treating hypertension in a warm blooded animal comprising administering to an animal in need of such treatment an effective mount of a compound of any one of claims 1 through 4.
- 9. A method of treating hypertension in a warm blooded animal comprising administering to an animal in need of such treatment an effective amount of a compound of claim 5.
- 10. A method of treating congestive heart failure in a warm blooded animal comprising administering to an animal in need of such treatment an effective amount of a compound of any of one claims 1 through 4.
- 11. A method of treating congestive heart failure in a warm blooded animal comprising administering to an animal in need of such treatment effective of a compound of claim 5.
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of application Ser. No. 07/929,455, filed Aug. 14, 1992, now abandoned which is a continuation-in-part of application Ser. No. 07/747,023, filed Aug. 19, 1991, now abandoned.
Foreign Referenced Citations (5)
Number |
Date |
Country |
0407342A2 |
Jun 1990 |
EPX |
0419048A |
Mar 1991 |
EPX |
0412594A |
Jul 1991 |
EPX |
0475898A1 |
Sep 1991 |
EPX |
WO9114679 |
Mar 1991 |
WOX |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
929455 |
Aug 1992 |
|
Parent |
747023 |
Aug 1991 |
|